With 0.82 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.51 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $24.9 whereas the lowest price it dropped to was $22.765. The 52-week range on STVN shows that it touched its highest point at $34.73 and its lowest point at $16.56 during that stretch. It currently has a 1-year price target of $26.11. With its current market cap of 6.59 billion, STVN has annualized dividend of $0.06 while the current yield stands at 0.25%. Beta for the stock currently stands at 0.59.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of STVN was up-trending over the past week, with a rise of 13.82%, but this was up by 13.38% over a month. Three-month performance surged to 20.97% while six-month performance rose 31.18%. The stock lost -18.04% in the past year, while it has lost -14.58% so far this year. A look at the trailing 12-month EPS for STVN yields 0.46 with Next year EPS estimates of 0.57. For the next quarter, that number is 0.19. This implies an EPS growth rate of -18.14% for this year and 15.15% for next year. EPS is expected to grow by 11.47% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 37.59%.
Float and Shares Shorts:
At present, 49.60 million STVN shares are outstanding with a float of 49.48 million shares on hand for trading. On 2024-11-29, short shares totaled 3.71 million, which was 136.0 higher than short shares on 1730332800. In addition to Mr. Franco Stevanato as the firm’s CEO & Executive Chairman, Mr. Marco Dal Lago serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 1.14143 of STVN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, STVN reported revenue of $277867000.0 and operating income of $41026000.0. The EBITDA in the recently reported quarter was $102415000.0 and diluted EPS was $0.11.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for STVN since 2 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With STVN analysts setting a high price target of 37.0 and a low target of 21.0, the average target price over the next 12 months is 26.3229. Based on these targets, STVN could surge 58.73% to reach the target high and fall by -9.91% to reach the target low. Reaching the average price target will result in a growth of 12.93% from current levels.
Analysts have provided yearly estimates in a range of $0.50663 being high and $0.46767 being low. For STVN, this leads to a yearly average estimate of $0.49689. Based on analyst estimates, the high estimate for the next quarter is $0.12 and the low estimate is $0.09. The average estimate for the next quarter is thus $0.1.
